Safety and Efficacy of Inhaled Insulin in Type 2 Diabetes

• Status: Terminated
• Trial end date: 2008-05-05
• Target enrollment: 0
• Participant gender: All

Summary

This trial is conducted in Asia, Europe and South America. The aim of this research is to compare the efficacy (reduction in HbA1c and blood glucose) and pulmonary safety (pulmonary function tests, chest x-rays) of mealtime inhaled insulin with subcutaneous insulin aspart both in combination with insulin detemir in Type 2 Diabetes.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novo Nordisk A/S
• Treatments: Insulin; Insulin Aspart; Insulin degludec, insulin aspart drug combination; Insulin Detemir; Insulin, Globin Zinc; Insulin, Long-Acting

Criteria

Inclusion Criteria:

• Type 2 diabetes

• Currently treated with insulin

• Body mass index of (BMI) less than or equal to 40.0 kg/m2

• HbA1c less than or equal to 11.0%

Exclusion Criteria:

• Total daily insulin dosage less than or equal to 100 IU or U/day

• Current smoking or smoking within the last 6 months

• Cardiac problems

• Uncontrolled hypertension

• Current proliferative retinopathy or maculopathy